XFOR X4 Pharmaceuticals, Inc.

2.790USD-0.71%Mkt Cap: 276.62M $P/E: 139.50

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an ora…

Key Statistics

Company
Market Cap276.62M USD
Enterprise Value143.89M USD
Revenue (TTM)15.85M USD
Gross Profit29.36M USD
Net Income (TTM)-79.20M USD
Revenue/Share0.16 USD
Last Price2.790 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees45
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)139.50
P/E (Forward)-3.61
PEG—
EV/EBITDA-1.82
EV/Revenue9.08
P/S17.33
P/B1.71
EPS (TTM)0.02
EPS (Forward)-0.77
52W Range
2.7004% of range4.830
52W High4.830 USD
52W Low2.700 USD
Profitability
Gross Margin83.60%
Oper. Margin-186.13%
EBITDA Margin0.00%
Profit Margin-225.55%
ROE-42.51%
ROA-27.27%
Growth
Revenue Growth346.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.62M USD
CapEx (TTM)3.00M USD
FCF Margin-336.41%
FCF Yield-19.27%
Net Debt-130.74M USD
Net Debt/EBITDA1.65
Balance Sheet
Debt/Equity0.41
Current Ratio11.30
Quick Ratio10.85
Book Value/Sh1.62 USD
Cash/Share2.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 14, 2019
Splits
Last Split1:30
Split DateApr 28, 2025
Analyst Consensus
Rating—
Target (Mean)11.60 USD
Upside (mean)+315.8%
Target Range10.00 USD – 13.00 USD
10.00+315.8% to mean13.00
# Analysts5
Ownership
Shares Out.99.15M
Float57.25M
Insiders0.44%
Institutions103.81%
Short Interest
Short Ratio9.6d
Short % Float8.32%
Short % Out.8.31%
Shares Short8.24M
Short (prev mo.)7.16M
Technical
SMA 503.788 (-26.3%)
SMA 2003.898 (-28.4%)
Beta0.46
S&P 52W Chg16.45%
Avg Vol (30d)1.02M
Avg Vol (10d)1.25M
Technical Indicators
RSI (14)27.7
MACD-0.2942
MACD Signal-0.2801
MACD Hist.-0.0142
BB Upper3.815 USD
BB Middle3.156 USD
BB Lower2.497 USD
BB Width41.75%
ATR (14)0.2009 USD
Vol Ratio (20d)0.67x